- Home
- Products
Pylarify (Piflufolastat F18)
Pylarify (Piflufolastat F18)
- Medicine Name: Pylarify
- Generic Name: Piflufolastat F18
- Dosage Form & Strength: Injection – multiple-dose vial with 37 MBq/mL to 2,960 MBq/mL (1 mCi/mL to 80 mCi/mL)
- Manufactured By: Progenics Pharmaceuticals, Inc.
Pylarify (Piflufolastat F18) is a radioactive diagnostic imaging agent used with positron emission tomography (PET) to detect prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer:
- With suspected metastasis and eligible for initial definitive treatment
- With suspected recurrence based on rising PSA levels
Recommended Dosage:
- 333 MBq (9 mCi) administered as a singleIV bolus injection
- Acceptable range: 296–370 MBq (8–10 mCi)
- Initiate PET imaging ~60 minutes post-injection
- Patient should void prior to scan
- Imaging to cover mid-thigh to skull vertex
Handling Note: This radioactive product must be handled only by trained professionals using appropriate shielding and safety procedures
Hydration & Radiation Safety: Encourage hydration before and after dosing to reduce radiation exposure. Frequent voiding recommended.
Imaging Limitations: False negatives or positives are possible. Interpretation must be done with clinical correlation.
Hypersensitivity Risk: Monitor for allergic reactions, especially in those with a history of drug/food allergies. Emergency support must be available.
Radiation Exposure: May increase long-term cancer risk. Proper handling is critical.
Use in Women: Not recommended. No data on use during breastfeeding.
Required Documents for Import:
- Valid prescription from a registered medical professional
- Diagnostic reports
- Patient’s government-issued ID
Order Confirmation:
- Orders are confirmed upon receipt of all required documents and applicable import permits
Availability in India & Globally: Global Rare Meds facilitates access to Pylarify for eligible patients in cities across India such as Mumbai, Delhi, Chennai, Pune, Kolkata, Hyderabad, Bangalore, Ahmedabad, and others. Support also available for Gulf and SAARC countries.
For Pricing & Orders:
- Phone/WhatsApp: +91-99675 15602
- Email: info@globalraremeds.com
Global Rare Meds sources Pylarify (Piflufolastat F18) from certified suppliers in the USA, Canada, Europe, and Australia. Dispensing is supervised by registered pharmacists, and products are shipped from our Ambernath, Thane District facility with cold chain and radiation shielding compliance.
We ensure fast turnaround, regulatory adherence, and global delivery capability.
What is the generic name of Pylarify®?
Piflufolastat F18
Who manufactures Pylarify®?
Progenics Pharmaceuticals, Inc.
Is Pylarify® FDA approved?
Yes. FDA approval granted on May 26, 2021
What is the dosage form of Pylarify®?
Clear, colorless radioactive solution in multi-dose vials ranging from 1 mCi/mL to 80 mCi/mL
What are the common side effects?
Fatigue, dysgeusia (taste disturbance), and headache
How is Pylarify® stored?
Store at 20°C–25°C (68°F–77°F) in its original shielded container. Use within 10 hours of synthesis completion.
Is it safe to order Pylarify® online in India?
Yes. Global Rare Meds ensures legally compliant, verified sourcing and delivery.
How much does Pylarify® cost in India?
Cost varies by source and logistics. Contact us directly for latest pricing.
How to order Pylarify®?
Submit your prescription and documents to info@globalraremeds.com or WhatsApp us at +91-99675 15602.
Is this product recommended for women?
No. Not intended for use in females due to lack of safety data
Contact Patient Support
If you have questions about your order, need assistance with documentation, or require support with medicine availability, our GlobalRareMeds Patient Support Team is here to help. We aim to respond within 24 hours, Monday to Friday, between 9:00 AM and 10:00 AM IST.
info@globalraremeds.com
Phone
+91 99675 15602
+91 99675 15602
Disclaimer
All trademarks, brands, and product names featured on this website are the property of their respective owners. GlobalRareMeds does not claim ownership or affiliation unless explicitly stated. Our role is to provide reliable and transparent access to difficult-to-source medicines through named-patient import services, based on valid prescriptions and legal requirements.
The product-related content on this website is shared to the best of our knowledge, compiled from publicly available sources and regulatory documents. However, GlobalRareMeds does not guarantee the accuracy, completeness, or timeliness of this information. We strongly recommend that all medical decisions, including usage and dosage, be made only in consultation with the prescribing doctor. GlobalRareMeds assumes no responsibility for consequences arising from reliance on this information without appropriate medical guidance
